GAINESVILLE, Fla., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, AGTC President and CEO, will present at two upcoming conferences.
Ms. Washer will be participating in three panel discussions at the 2014 BioFlorida Conference in Ft. Lauderdale, Florida:
- On Monday, October 13th, at 9:35am ET, Ms. Washer will participate in one of the conference's BioBusiness sections, "Spotlight on the Innovation in Florida."
- On Monday, October 13th, at 4:50pm ET, Ms. Washer will moderate one of the conference's keynote panels, "The Future Is Here: Building for Success."
- On Tuesday, October 14th, at 9:30am ET, Ms. Washer will participate in a panel entitled "BioScience: Seeing the Future: Advances in Ophthalmology Research and Technology."
Ms. Washer will also participate in a panel discussion at the Ophthalmology Innovation Summit (OIS) in Chicago. The panel, "IPOs in Ophthalmology – The Class of 2014 and Beyond," will take place on Thursday, October 16th at 4:10pm CT.
About AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes, that significantly affect visual function and currently lack effective medical treatments. AGTC has recently begun development of a product to treat Wet AMD using the company's experience in ophthalmology to expand into disease indications with larger markets.